ArticleAnnals of surgical oncology2026
Changes in Outcomes of Hepatic Cytoreduction for Neuroendocrine Liver Metastases over Two Decades: From Major Hepatectomy to Parenchyma-Sparing Approaches.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical and systemic management of neuroendocrine liver metastases (NELM) has evolved over the past decades. This study aimed to evaluate temporal changes in prognosis and identify factors associated with improved survival after hepatic cytoreduction for NELM. PATIENTS AND
methodsPatients who underwent hepatic cytoreduction for NELM during 1998-2023 were retrospectively analyzed and divided into earlier period (EP, 1998-2008) and later period (LP, 2009-2023) cohorts. Clinicopathological features, perioperative outcomes, and survival were compared. Covariate-adjusted survival curves and propensity score matching were used to compare overall survival (OS) between major hepatectomy and liver-parenchyma-sparing cytoreduction (LPSC).
resultsThe study included 293 patients, 132 in the EP cohort and 161 in the LP cohort. The LP cohort had a lower rate of major hepatectomy (32.9% versus 60.0%, P < 0.001) and significantly better OS (10-year OS rate, 67.4% versus 44.2%, P < 0.001). Major hepatectomy remained independently associated with worse OS after adjustment for treatment period and other covariates [hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.02-2.98, P = 0.043]. This association was consistent after propensity score matching. LP patients received local therapy (including surgery, percutaneous ablation, and transarterial embolization), somatostatin analogs, and targeted agents more frequently than EP patients after tumor progression.
conclusionsOS after hepatic cytoreduction for NELM improved during 1998-2023 in parallel with a shift from extensive resections to a parenchyma-sparing approach and the integration of modern systemic therapies. These findings support individualized cytoreductive strategies that balance tumor reduction with preservation of liver parenchyma and future treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.